Browsing by Author Sarah Cannon Research Institute

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)
1-Jan-2014Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2H. S. Rugo; K. I. Pritchard; M. Gnant; S. Noguchi; M. Piccart; G. Hortobagyi; J. Baselga; A. Perez; M. Geberth; T. Csoszi; E. Chouinard; V. Srimuninnimit; P. Puttawibul; J. Eakle; W. Feng; H. Bauly; M. El-hashimy; T. Taran; H. A. Burris; UCSF Helen Diller Family Comprehensive Cancer Center; University of Toronto; Medizinische Universitat Wien; Osaka University; Institut Jules Bordet; University of Texas MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Memorial Cancer Institute; Praxisklinic am Rosengarten Mannheim; Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Cambridge Memorial Hospital; Mahidol University; Prince of Songkla University; Novartis Pharmaceuticals Corporation; Novartis Pharma AG; Sarah Cannon Research Institute
1-May-2016Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialA. Hochhaus; G. Saglio; T. P. Hughes; R. A. Larson; D. W. Kim; S. Issaragrisil; P. D. Le Coutre; G. Etienne; P. E. Dorlhiac-Llacer; R. E. Clark; I. W. Flinn; H. Nakamae; B. Donohue; W. Deng; D. Dalal; H. D. Menssen; H. M. Kantarjian; Universitatsklinikum Jena und Medizinische Fakultat; Università degli Studi di Torino; The University of Adelaide; University of Chicago; The Catholic University of Korea; Mahidol University; Charité – Universitätsmedizin Berlin; Institut Bergonie; Universidade de Sao Paulo - USP; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Sarah Cannon Research Institute; Osaka City University; Novartis Pharmaceuticals Corporation; Novartis International AG; University of Texas MD Anderson Cancer Center
1-Jan-2013Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Kathleen I. Pritchard; Howard A. Burris; Yoshinori Ito; Hope S. Rugo; Shaker Dakhil; Gabriel N. Hortobagyi; Mario Campone; Tibor Csöszi; José Baselga; Puttisak Puttawibul; Martine Piccart; Daniel Heng; Shinzaburo Noguchi; Vichien Srimuninnimit; Hugues Bourgeois; Antonio Gonzalez Martin; Karen Osborne; Ashok Panneerselvam; Tetiana Taran; Tarek Sahmoud; Michael Gnant; University of Toronto; Sarah Cannon Research Institute; Cancer Institute Hospital of Japan Foundation for Cancer Research; UCSF Helen Diller Family Comprehensive Cancer Center; Cancer Center of Kansas; University of Texas MD Anderson Cancer Center; Centre de Recherche en Cancérologie; Hetenyi Geza County Hospital; Memorial Sloan-Kettering Cancer Center; Prince of Songkla University; Institut Jules Bordet; University of Calgary; Osaka University; Mahidol University; Centre Jean Bernard; MD Anderson Cancer Center, Madrid; Novartis International AG; Novartis Pharmaceuticals Corporation; Medizinische Universitat Wien